373 related articles for article (PubMed ID: 31899799)
41. RUNX1 and CBFβ Mutations and Activities of Their Wild-Type Alleles in AML.
Hyde RK; Liu P; Friedman AD
Adv Exp Med Biol; 2017; 962():265-282. PubMed ID: 28299663
[TBL] [Abstract][Full Text] [Related]
42. Prognostic Impacts of D816V
Cho BS; Min GJ; Park SS; Park S; Jeon YW; Shin SH; Yahng SA; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Wook-Lee J; Kim MS; Kim YG; Kim HJ
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33477584
[TBL] [Abstract][Full Text] [Related]
43. Combination of eriocalyxin B and homoharringtonine exerts synergistic anti-tumor effects against t(8;21) AML.
Lei YC; Chen XJ; Dai YT; Dai B; Wang JY; Li MH; Liu P; Liu H; Wang KK; Jiang L; Chen B
Acta Pharmacol Sin; 2024 Mar; 45(3):633-645. PubMed ID: 38017299
[TBL] [Abstract][Full Text] [Related]
44. Detection of a novel CBFB/MYH11 variant fusion transcript (K-type) showing partial insertion of exon 6 of CBFB gene using two commercially available multiplex RT-PCR kits.
Park TS; Lee ST; Song J; Lee KA; Lee JH; Kim J; Lee HJ; Han JH; Kim JK; Cho SR; Choi JR
Cancer Genet Cytogenet; 2009 Mar; 189(2):87-92. PubMed ID: 19215788
[TBL] [Abstract][Full Text] [Related]
45. The clinical mutatome of core binding factor leukemia.
Opatz S; Bamopoulos SA; Metzeler KH; Herold T; Ksienzyk B; Bräundl K; Tschuri S; Vosberg S; Konstandin NP; Wang C; Hartmann L; Graf A; Krebs S; Blum H; Schneider S; Thiede C; Middeke JM; Stölzel F; Röllig C; Schetelig J; Ehninger G; Krämer A; Braess J; Görlich D; Sauerland MC; Berdel WE; Wörmann BJ; Hiddemann W; Spiekermann K; Bohlander SK; Greif PA
Leukemia; 2020 Jun; 34(6):1553-1562. PubMed ID: 31896782
[TBL] [Abstract][Full Text] [Related]
46. [Molecular Genetic Characteristics of Acute Myeloid Leukemia Patients with
Jiang Y; Chao HY; Lu XZ; Wu P; Sun XC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1661-1667. PubMed ID: 36476886
[TBL] [Abstract][Full Text] [Related]
47. Core binding factor acute myeloid leukaemia and c-KIT mutations.
Riera L; Marmont F; Toppino D; Frairia C; Sismondi F; Audisio E; Di Bello C; D'Ardia S; Di Celle PF; Messa E; Inghirami G; Vitolo U; Pich A
Oncol Rep; 2013 May; 29(5):1867-72. PubMed ID: 23467883
[TBL] [Abstract][Full Text] [Related]
48. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.
Gaidzik VI; Bullinger L; Schlenk RF; Zimmermann AS; Röck J; Paschka P; Corbacioglu A; Krauter J; Schlegelberger B; Ganser A; Späth D; Kündgen A; Schmidt-Wolf IG; Götze K; Nachbaur D; Pfreundschuh M; Horst HA; Döhner H; Döhner K
J Clin Oncol; 2011 Apr; 29(10):1364-72. PubMed ID: 21343560
[TBL] [Abstract][Full Text] [Related]
49. Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA.
Duployez N; Nibourel O; Marceau-Renaut A; Willekens C; Helevaut N; Caillault A; Villenet C; Celli-Lebras K; Boissel N; Jourdan E; Dombret H; Figeac M; Preudhomme C; Renneville A
Am J Hematol; 2014 Jun; 89(6):610-5. PubMed ID: 24616160
[TBL] [Abstract][Full Text] [Related]
50. The impact of the combination of KIT mutation and minimal residual disease on outcome in t(8;21) acute myeloid leukemia.
Qin YZ; Jiang Q; Wang Y; Jiang H; Xu LP; Zhao XS; Zhang XH; Liu KY; Huang XJ
Blood Cancer J; 2021 Apr; 11(4):67. PubMed ID: 33795645
[No Abstract] [Full Text] [Related]
51. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients.
Kihara R; Nagata Y; Kiyoi H; Kato T; Yamamoto E; Suzuki K; Chen F; Asou N; Ohtake S; Miyawaki S; Miyazaki Y; Sakura T; Ozawa Y; Usui N; Kanamori H; Kiguchi T; Imai K; Uike N; Kimura F; Kitamura K; Nakaseko C; Onizuka M; Takeshita A; Ishida F; Suzushima H; Kato Y; Miwa H; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Ogawa S; Naoe T
Leukemia; 2014 Aug; 28(8):1586-95. PubMed ID: 24487413
[TBL] [Abstract][Full Text] [Related]
52. Clinical impact of c-KIT and CEBPA mutations in 33 patients with corebinding factor (Non-M3) acute myeloid leukemia.
Mao X; Yin R; Liu L; Zhou Y; Yang C; Fang C; Jiang H; Guo Q; Tian X
Pediatr Neonatol; 2023 Jul; 64(4):435-441. PubMed ID: 36809862
[TBL] [Abstract][Full Text] [Related]
53. Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study.
Kawashima N; Akashi A; Nagata Y; Kihara R; Ishikawa Y; Asou N; Ohtake S; Miyawaki S; Sakura T; Ozawa Y; Usui N; Kanamori H; Ito Y; Imai K; Suehiro Y; Kitamura K; Sakaida E; Takeshita A; Suzushima H; Naoe T; Matsumura I; Miyazaki Y; Ogawa S; Kiyoi H;
Ann Hematol; 2019 Jan; 98(1):83-91. PubMed ID: 30251205
[TBL] [Abstract][Full Text] [Related]
54. RUNX1 repression-independent mechanisms of leukemogenesis by fusion genes CBFB-MYH11 and AML1-ETO (RUNX1-RUNX1T1).
Hyde RK; Liu PP
J Cell Biochem; 2010 Aug; 110(5):1039-45. PubMed ID: 20589720
[TBL] [Abstract][Full Text] [Related]
55. [Genetic abnormalities in core binding factor acute myeloid leukemia].
Ishikawa Y
Rinsho Ketsueki; 2017; 58(8):991-998. PubMed ID: 28883285
[TBL] [Abstract][Full Text] [Related]
56. Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial.
Willekens C; Blanchet O; Renneville A; Cornillet-Lefebvre P; Pautas C; Guieze R; Ifrah N; Dombret H; Jourdan E; Preudhomme C; Boissel N;
Haematologica; 2016 Mar; 101(3):328-35. PubMed ID: 26635039
[TBL] [Abstract][Full Text] [Related]
57. Rare CBFB-MYH11 fusion transcripts in AML with inv(16)/t(16;16) are associated with therapy-related AML M4eo, atypical cytomorphology, atypical immunophenotype, atypical additional chromosomal rearrangements and low white blood cell count: a study on 162 patients.
Schnittger S; Bacher U; Haferlach C; Kern W; Haferlach T
Leukemia; 2007 Apr; 21(4):725-31. PubMed ID: 17287858
[TBL] [Abstract][Full Text] [Related]
58. Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome.
Marková J; Marková J; Trnková Z; Michková P; Maaloufová J; Starý J; Cetkovský P; Schwarz J
Leuk Lymphoma; 2009 Sep; 50(9):1448-60. PubMed ID: 19603346
[TBL] [Abstract][Full Text] [Related]
59. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.
Pollard JA; Alonzo TA; Gerbing RB; Ho PA; Zeng R; Ravindranath Y; Dahl G; Lacayo NJ; Becton D; Chang M; Weinstein HJ; Hirsch B; Raimondi SC; Heerema NA; Woods WG; Lange BJ; Hurwitz C; Arceci RJ; Radich JP; Bernstein ID; Heinrich MC; Meshinchi S
Blood; 2010 Mar; 115(12):2372-9. PubMed ID: 20056794
[TBL] [Abstract][Full Text] [Related]
60. Minimal residual disease (MRD) monitoring and mutational landscape in AML with RUNX1-RUNX1T1: a study on 134 patients.
Höllein A; Jeromin S; Meggendorfer M; Fasan A; Nadarajah N; Kern W; Haferlach C; Haferlach T
Leukemia; 2018 Oct; 32(10):2270-2274. PubMed ID: 29568097
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
